This information was published on 2025-11-17T11:29:04 for IP Right Registration Published.
| Field | Value |
| (210) | 2583718 (IR 1873614) |
| (220) |
22 Jul 2025
|
| (300) |
US, 06 Feb 2025, 99031165
|
| (511) (510) |
Class 5
Pharmaceuticals and medicines for the treatment of cystic fibrosis, pain, sickle cell disease, beta thalassemia, muscular dystrophy, diabetes, respiratory diseases, liver disease, kidney disease, alpha-1 antitrypsin deficiency and APOL1-mediated kidney disease. |
| (540) | VOXFINLY |
| (550) | Word |
| (730) |
Vertex Pharmaceuticals Incorporated
|
Find out more about publications on the About page.